Update on Hepatitis A Management.

JAMA

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.

Published: January 2021

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899142PMC
http://dx.doi.org/10.1001/jama.2020.22804DOI Listing

Publication Analysis

Top Keywords

update hepatitis
4
hepatitis management
4
update
1
management
1

Similar Publications

Monocyte chemoattractant protein-1 (MCP-1) is regarded as a crucial proinflammatory cytokine that controls the migration and entry of macrophages. It has been demonstrated that chemokine ligand 2 and its receptor, Chemokine receptor 2, are both implicated in several liver disorders. In a similar context, immunity mediators are overexpressed and stimulated by MCP-1.

View Article and Find Full Text PDF

[Updates in General Management and Frequent Complications Following Adult Liver Transplant].

Rev Med Chil

June 2024

Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Liver transplantation (LT) is a cost-effective therapy for advanced liver disease. Although LT significantly improves long-term survival, it requires strict control of immunosuppressants and their potential complications. Several available immunosuppressive drugs include glucocorticoids, calcineurin inhibitors, mycophenolate, mTOR inhibitors, and anti-CD25 antibodies.

View Article and Find Full Text PDF

The intersection between metabolic-associated steatotic liver disease (MASLD) and chronic hepatitis B virus (HBV) infection is an emerging area of research with significant implications for public health and clinical practice. Wang 's study highlights the complexities of managing patients with concurrent MASLD and HBV. The findings revealed that patients with concurrent MASLD-HBV exhibited more severe liver inflammation and fibrosis, whereas those with HBV alone presented a better lipid profile.

View Article and Find Full Text PDF

Advancing hepatitis B elimination: A systematic review of global immunization progress and future directions.

Diagn Microbiol Infect Dis

December 2024

Molecular Biology Laboratory, Institut Pasteur du Maroc, Casablanca, Morocco.

The World Health Organization (WHO) has set a target of eliminating viral hepatitis B and C by 2030. Vaccination against hepatitis B (HepB) remains the most effective strategy for controlling and eliminating Hepatitis B Virus (HBV) infection. The development of HepB vaccines started with plasma-derived vaccines, which have since been largely replaced by safer and more effective recombinant vaccines, now considered the gold standard for preventing HBV infections.

View Article and Find Full Text PDF

Periodontitis is the inflammation of the supporting structures around the dentition. Several microbial agents, mostly bacteria, have been identified as causative factors for periodontal disease. On the other hand, oral cavity is a rich reservoir for viruses since it contains a wide variety of cell types that can be targeted by viruses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!